menu
    • menu
    [{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Merdury Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Interferon Alfa","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Ainos","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Ainos"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Lind Partners"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Not Applicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Undisclosed"},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","graph1":null,"graph2":null,"graph3":"Ainos","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ainos \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Ainos

    Menu

    Ainos

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ainos Plans Taiwan Study for VELDONA in HIV-Related Oral Warts

                            Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 17, 2024

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $9.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ainos Raises $9 Million in Growth Capital with Existing Shareholder

                            Details : The financing will be used to advance company's products including VELDONA (interferon alfa) which binds to type I interferon receptors (IFNAR). It is being evaluated for thrombocytopenia.

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 07, 2024

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $9.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ainos Submits Clinical Hold Response to FDA for VELDONA Trial Against Mild COVID-19

                            Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated in phase 1 clinial trials for the treatment of mild COVID-19 symptoms.

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 05, 2024

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Lind Partners

                            Deal Size : $1.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ainos Announces $1.75 Million Follow-On Funding

                            Details : Veldona (interferon alfa) is progressing towards IND applications for human drug candidates and co-development of VOC sensing tech using AI Nose.

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 24, 2024

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Lind Partners

                            Deal Size : $1.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Wa...

                            Details : Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 21, 2023

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Sero...

                            Details : Veldona is a low-dose oral interferon formulation investigated as a potential treatment for oral warts in HIV-seropositive patients. Ainos plans to pursue a pre-IND meeting with the U.S. FDA in advance of planned Phase III clinical studies for the drug c...

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 18, 2023

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Merdury Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in H...

                            Details : Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts i...

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 14, 2023

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Merdury Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VEL...

                            Details : Veldona, a low-dose oral interferon-alpha formulation to boost the human body’s frontline defenses against disease and infection. IFN-α is a key component of our body’s innate immune response to viral infection. Most cells in the body will produce i...

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 31, 2022

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low...

                            Details : A pre-clinical animal study we conducted since March of this year validated the effectiveness of our low-dose oral Veldona (interferon) therapy to protect against COVID-19.

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 24, 2022

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth